Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic Review

Background. Chronic hepatitis B (CHB) patients with normal or minimally increased levels of alanine aminotransferase (ALT) are still at the risk of hepatocellular carcinoma, cirrhotic events, and mortality. However, there is a debate over the initiation of antiviral treatment for these patients. Thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiyao Chen, Xingrong Zheng, Hewei Wu, Boxiang Zhang, Liang Peng, Chan Xie
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Canadian Journal of Gastroenterology and Hepatology
Online Access:http://dx.doi.org/10.1155/2022/7499492
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850172679398621184
author Xiyao Chen
Xingrong Zheng
Hewei Wu
Boxiang Zhang
Liang Peng
Chan Xie
author_facet Xiyao Chen
Xingrong Zheng
Hewei Wu
Boxiang Zhang
Liang Peng
Chan Xie
author_sort Xiyao Chen
collection DOAJ
description Background. Chronic hepatitis B (CHB) patients with normal or minimally increased levels of alanine aminotransferase (ALT) are still at the risk of hepatocellular carcinoma, cirrhotic events, and mortality. However, there is a debate over the initiation of antiviral treatment for these patients. This systematic review and mate-analysis aimed to explore this problem. Methods. MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science databases were systematically searched for retrieving relevant studies with risk ratios (RRs) or risk differences (RDs) for virological changes between antivirus-treated and no antivirus-treated CHB patients with ALT levels less than two-fold of the upper limit of normal. Retrieved data ranged from January 1990 to October 2020. Results. Of 6783 abstracts screened, 9 studies met the criteria for inclusion in the systematic review and had a low risk of bias. Among studies that were involved in the meta-analyses, it was found that the rates of HBsAg loss (RR = 12.22, 95% confidence interval (CI): 4.28–34.95, P<0.001), HBsAg seroconversion (RR = 19.90, 95% CI: 2.75–144.09, P=0.003), and undetectable HBV DNA (RR = 11.89, 95% CI: 2.44–57.89, P=0.002) were both higher in the antiviral treatment group compared with placebo or no treatment group. Subgroup analysis suggested that patients who received interferon (IFN)-based therapy were more inclined to achieve HBsAg loss (P=0.010), HBsAg seroconversion (P=0.020), and HBeAg loss (P=0.002). Conclusion. From a sizable population, it was revealed that CHB patients with normal or minimally increased levels of ALT could benefit from the antiviral therapy, especially those who received IFN-based treatment.
format Article
id doaj-art-ce1425fdb6af4e40a17b4d77a3f964fc
institution OA Journals
issn 2291-2797
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Canadian Journal of Gastroenterology and Hepatology
spelling doaj-art-ce1425fdb6af4e40a17b4d77a3f964fc2025-08-20T02:20:01ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27972022-01-01202210.1155/2022/7499492Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic ReviewXiyao Chen0Xingrong Zheng1Hewei Wu2Boxiang Zhang3Liang Peng4Chan Xie5Department of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesBackground. Chronic hepatitis B (CHB) patients with normal or minimally increased levels of alanine aminotransferase (ALT) are still at the risk of hepatocellular carcinoma, cirrhotic events, and mortality. However, there is a debate over the initiation of antiviral treatment for these patients. This systematic review and mate-analysis aimed to explore this problem. Methods. MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science databases were systematically searched for retrieving relevant studies with risk ratios (RRs) or risk differences (RDs) for virological changes between antivirus-treated and no antivirus-treated CHB patients with ALT levels less than two-fold of the upper limit of normal. Retrieved data ranged from January 1990 to October 2020. Results. Of 6783 abstracts screened, 9 studies met the criteria for inclusion in the systematic review and had a low risk of bias. Among studies that were involved in the meta-analyses, it was found that the rates of HBsAg loss (RR = 12.22, 95% confidence interval (CI): 4.28–34.95, P<0.001), HBsAg seroconversion (RR = 19.90, 95% CI: 2.75–144.09, P=0.003), and undetectable HBV DNA (RR = 11.89, 95% CI: 2.44–57.89, P=0.002) were both higher in the antiviral treatment group compared with placebo or no treatment group. Subgroup analysis suggested that patients who received interferon (IFN)-based therapy were more inclined to achieve HBsAg loss (P=0.010), HBsAg seroconversion (P=0.020), and HBeAg loss (P=0.002). Conclusion. From a sizable population, it was revealed that CHB patients with normal or minimally increased levels of ALT could benefit from the antiviral therapy, especially those who received IFN-based treatment.http://dx.doi.org/10.1155/2022/7499492
spellingShingle Xiyao Chen
Xingrong Zheng
Hewei Wu
Boxiang Zhang
Liang Peng
Chan Xie
Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic Review
Canadian Journal of Gastroenterology and Hepatology
title Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic Review
title_full Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic Review
title_fullStr Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic Review
title_full_unstemmed Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic Review
title_short Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic Review
title_sort virological changes of chronic hepatitis b patients with minimally elevated levels of alanine aminotransferase a meta analysis and systematic review
url http://dx.doi.org/10.1155/2022/7499492
work_keys_str_mv AT xiyaochen virologicalchangesofchronichepatitisbpatientswithminimallyelevatedlevelsofalanineaminotransferaseametaanalysisandsystematicreview
AT xingrongzheng virologicalchangesofchronichepatitisbpatientswithminimallyelevatedlevelsofalanineaminotransferaseametaanalysisandsystematicreview
AT heweiwu virologicalchangesofchronichepatitisbpatientswithminimallyelevatedlevelsofalanineaminotransferaseametaanalysisandsystematicreview
AT boxiangzhang virologicalchangesofchronichepatitisbpatientswithminimallyelevatedlevelsofalanineaminotransferaseametaanalysisandsystematicreview
AT liangpeng virologicalchangesofchronichepatitisbpatientswithminimallyelevatedlevelsofalanineaminotransferaseametaanalysisandsystematicreview
AT chanxie virologicalchangesofchronichepatitisbpatientswithminimallyelevatedlevelsofalanineaminotransferaseametaanalysisandsystematicreview